Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-03

Clinical Trial Update: IL1 Inhibition in FOP

View source ↗

Summary

A clinical trial is evaluating an IL-1–inhibiting therapy for fibrodysplasia ossificans progressiva and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Investigational IL-1 inhibitor (Interleukin-1 inhibitor)

Snippet

Sponsor: University of California, San Francisco | Conditions: Fibrodysplasia Ossificans Progressiva (FOP) | Status: RECRUITING